bivalent opv
Vaccineexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01813604)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- PoliovirusImmunity, active
Poliovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bivalent opv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05794230 | Phase 3 | Mar 27, 2023 | Sanofi-Aventis |
| NCT04540185 | Phase 3 | Nov 1, 2020 | Biomed Industries, Inc., Coronavirus Research Institute, NeuroActiva |
| NCT01813604 | Phase 3 | Nov 1, 2012 | Centers for Disease Control and Prevention (CDC), Government of Bangladesh, International Center for Diarrheal Disease Research, NanoPass Technologies Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biomed Industries, Inc. | For profit | 1 | 0 | 1 | 2020 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 1 | 1 | 2012 |
| Coronavirus Research Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Government of Bangladesh | Academic/Hospital | 1 | 0 | 1 | 2012 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 1 | 0 | 1 | 2012 |
| NanoPass Technologies Ltd | For profit | 1 | 0 | 1 | 2012 |
| NeuroActiva | For profit | 1 | 1 | 1 | 2020 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2023 |
8 organizations
Page 1 / 1